Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Review article: Biomedical intelligence

Vol. 147 No. 4950 (2017)

The perioperative use of synthetic and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis

  • Gregory Fleury
  • Sylvano Mania
  • Didier Hannouche
  • Cem Gabay
DOI
https://doi.org/10.4414/smw.2017.14563
Cite this as:
Swiss Med Wkly. 2017;147:w14563
Published
11.12.2017

Summary

Disease-modifying antirheumatic drugs (DMARDs) have become essential treatments in the management of patients with inflammatory rheumatic diseases. Their use has resulted in a marked improvement of disease control and a limitation of joint damage, although some patients still require subsequent corrective or joint replacement surgery. Due to their immunosuppressive effects, some DMARDs are associated with an increased risk of infection. The aim of this review is to discuss the available literature on the management of DMARDs during the perioperative period, particularly in the case of orthopaedic surgery. Conventional synthetic DMARDs such as methotrexate, sulfasalazine, leflunomide, hydroxychloroquine appear to be safe during the perioperative period. Conflicting results on biological DMARDs, mainly tumour necrosis factor antagonists, are reported in the literature, including both increased and unchanged risk of superimposed infections after surgery. Taking into account the available literature, we included some propositions for the management of patients who will undergo surgical interventions.

References

  1. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–77. doi:.https://doi.org/10.1136/annrheumdis-2016-210715
  2. Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol. 2016;12(1):49–62. doi:.https://doi.org/10.1038/nrrheum.2015.169
  3. Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015;386(9990):258–65. doi:.https://doi.org/10.1016/S0140-6736(14)61704-9
  4. Koyama K, Ohba T, Ebata S, Haro H. Postoperative Surgical Infection After Spinal Surgery in Rheumatoid Arthritis. Orthopedics. 2016;39(3):e430–3. doi:.https://doi.org/10.3928/01477447-20160404-05
  5. Kang C-N, Kim C-W, Moon J-K. The outcomes of instrumented posterolateral lumbar fusion in patients with rheumatoid arthritis. Bone Joint J. 2016;98-B(1):102–8. doi:.https://doi.org/10.1302/0301-620X.98B1.36247
  6. LoVerde ZJ, Mandl LA, Johnson BK, Figgie MP, Boettner F, Lee Y-Y, et al. Rheumatoid Arthritis Does Not Increase Risk of Short-term Adverse Events after Total Knee Arthroplasty: A Retrospective Case-control Study. J Rheumatol. 2015;42(7):1123–30. doi:.https://doi.org/10.3899/jrheum.141251
  7. Schrama JC, Fenstad AM, Dale H, Havelin L, Hallan G, Overgaard S, et al. Increased risk of revision for infection in rheumatoid arthritis patients with total hip replacements. Acta Orthop. 2015;86(4):469–76. doi:.https://doi.org/10.3109/17453674.2015.1017793
  8. Singh JA, Inacio MCS, Namba RS, Paxton EW. Rheumatoid arthritis is associated with higher ninety-day hospital readmission rates compared to osteoarthritis after hip or knee arthroplasty: a cohort study. Arthritis Care Res (Hoboken). 2015;67(5):718–24. doi:.https://doi.org/10.1002/acr.22497
  9. Ravi B, Croxford R, Hollands S, Paterson JM, Bogoch E, Kreder H, et al. Increased risk of complications following total joint arthroplasty in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66(2):254–63. doi:.https://doi.org/10.1002/art.38231
  10. Pedersen E, Pinsker E, Younger ASE, Penner MJ, Wing KJ, Dryden PJ, et al. Outcome of total ankle arthroplasty in patients with rheumatoid arthritis and noninflammatory arthritis. A multicenter cohort study comparing clinical outcome and safety. J Bone Joint Surg Am. 2014;96(21):1768–75. doi:.https://doi.org/10.2106/JBJS.M.01164
  11. Carroll K, Dowsey M, Choong P, Peel T. Risk factors for superficial wound complications in hip and knee arthroplasty. Clin Microbiol Infect. 2014;20(2):130–5. doi:.https://doi.org/10.1111/1469-0691.12209
  12. Stundner O, Danninger T, Chiu Y-L, Sun X, Goodman SM, Russell LA, et al. Rheumatoid arthritis vs osteoarthritis in patients receiving total knee arthroplasty: perioperative outcomes. J Arthroplasty. 2014;29(2):308–13. doi:.https://doi.org/10.1016/j.arth.2013.05.008
  13. Hsieh P-H, Huang K-C, Shih H-N. Prosthetic joint infection in patients with rheumatoid arthritis: an outcome analysis compared with controls. PLoS One. 2013;8(8):e71666. doi:.https://doi.org/10.1371/journal.pone.0071666
  14. Pahys JM, Pahys JR, Cho SK, Kang MM, Zebala LP, Hawasli AH, et al. Methods to decrease postoperative infections following posterior cervical spine surgery. J Bone Joint Surg Am. 2013;95(6):549–54. doi:.https://doi.org/10.2106/JBJS.K.00756
  15. Michaud K, Fehringer EV, Garvin K, O’Dell JR, Mikuls TR. Rheumatoid arthritis patients are not at increased risk for 30-day cardiovascular events, infections, or mortality after total joint arthroplasty. Arthritis Res Ther. 2013;15(6):R195. doi:.https://doi.org/10.1186/ar4385
  16. Bhatia R, Desouza RM, Bull J, Casey ATH. Rigid occipitocervical fixation: indications, outcomes, and complications in the modern era. J Neurosurg Spine. 2013;18(4):333–9. doi:.https://doi.org/10.3171/2013.1.SPINE12645
  17. da Cunha BM, de Oliveira SB, Santos-Neto L. Incidence of infectious complications in hip and knee arthroplasties in rheumatoid arthritis and osteoarthritis patients. Rev Bras Reumatol. 2011;51(6):609–15.
  18. SooHoo NF, Farng E, Lieberman JR, Chambers L, Zingmond DS. Factors that predict short-term complication rates after total hip arthroplasty. Clin Orthop Relat Res. 2010;468(9):2363–71. doi:.https://doi.org/10.1007/s11999-010-1354-0
  19. Schrama JC, Espehaug B, Hallan G, Engesaeter LB, Furnes O, Havelin LI, et al. Risk of revision for infection in primary total hip and knee arthroplasty in patients with rheumatoid arthritis compared with osteoarthritis: a prospective, population-based study on 108,786 hip and knee joint arthroplasties from the Norwegian Arthroplasty Register. Arthritis Care Res (Hoboken). 2010;62(4):473–9. doi:.https://doi.org/10.1002/acr.20036
  20. van der Heide HJL, Schutte B, Louwerens JWK, van den Hoogen FHJ, de Waal Malefijt MC. Total ankle prostheses in rheumatoid arthropathy: Outcome in 52 patients followed for 1-9 years. Acta Orthop. 2009;80(4):440–4. doi:.https://doi.org/10.3109/17453670903153568
  21. Jämsen E, Huhtala H, Puolakka T, Moilanen T. Risk factors for infection after knee arthroplasty. A register-based analysis of 43,149 cases. J Bone Joint Surg Am. 2009;91(1):38–47. doi:.https://doi.org/10.2106/JBJS.G.01686
  22. Bongartz T, Halligan CS, Osmon DR, Reinalda MS, Bamlet WR, Crowson CS, et al. Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Rheum. 2008;59(12):1713–20. doi:.https://doi.org/10.1002/art.24060
  23. Himanen A-K, Belt EA, Lehto MUK, Hämäläinen MMJ. A comparison of survival of moulded monoblock and modular tibial components of 751 AGC total knee replacements in the treatment of rheumatoid arthritis. J Bone Joint Surg Br. 2007;89-B(5):609–14. doi:.https://doi.org/10.1302/0301-620X.89B5.17950
  24. Ljung P, Jonsson K, Rydholm U. Short-term complications of the lateral approach for non-constrained elbow replacement. Follow-up of 50 rheumatoid elbows. J Bone Joint Surg Br. 1995;77(6):937–42.
  25. Kristensen O, Nafei A, Kjaersgaard-Andersen P, Hvid I, Jensen J. Long-term results of total condylar knee arthroplasty in rheumatoid arthritis. J Bone Joint Surg Br. 1992;74(6):803–6.
  26. Wymenga AB, van Horn JR, Theeuwes A, Tmuytjens HL, Slooff TJ. Perioperative factors associated with septic arthritis after arthroplasty. Prospective multicenter study of 362 knee and 2,651 hip operations. Acta Orthop Scand. 1992;63(6):665–71. doi:.https://doi.org/10.1080/17453679209169732
  27. Wilson MG, Kelley K, Thornhill TS. Infection as a complication of total knee-replacement arthroplasty. Risk factors and treatment in sixty-seven cases. J Bone Joint Surg Am. 1990;72(6):878–83. doi:.https://doi.org/10.2106/00004623-199072060-00013
  28. Poss R, Ewald FC, Thomas WH, Sledge CB. Complications of total hip-replacement arthorplasty in patients with rheumatoid arthritis. J Bone Joint Surg Am. 1976;58(8):1130–3. doi:.https://doi.org/10.2106/00004623-197658080-00016
  29. Garner RW, Mowat AG, Hazleman BL. Wound healing after operations of patients with rheumatoid arthritis. J Bone Joint Surg Br. 1973;55(1):134–44.
  30. Luessenhop CP, Higgins LD, Brause BD, Ranawat CS. Multiple prosthetic infections after total joint arthroplasty. Risk factor analysis. J Arthroplasty. 1996;11(7):862–8. doi:.https://doi.org/10.1016/S0883-5403(96)80189-6
  31. Grennan DM, Gray J, Loudon J, Fear S. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis. 2001;60(3):214–7. doi:.https://doi.org/10.1136/ard.60.3.214
  32. Sreekumar R, Gray J, Kay P, Grennan DM. Methotrexate and post operative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery--a ten year follow-up. Acta Orthop Belg. 2011;77(6):823–6.
  33. Murata K, Yasuda T, Ito H, Yoshida M, Shimizu M, Nakamura T. Lack of increase in postoperative complications with low-dose methotrexate therapy in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Mod Rheumatol. 2006;16(1):14–9. doi:.https://doi.org/10.3109/s10165-005-0444-4
  34. Jain A, Witbreuk M, Ball C, Nanchahal J. Influence of steroids and methotrexate on wound complications after elective rheumatoid hand and wrist surgery. J Hand Surg Am. 2002;27(3):449–55. doi:.https://doi.org/10.1053/jhsu.2002.32958
  35. Sany J, Anaya JM, Canovas F, Combe B, Jorgensen C, Saker S, et al. Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis. J Rheumatol. 1993;20(7):1129–32.
  36. Carpenter MT, West SG, Vogelgesang SA, Casey Jones DE. Postoperative joint infections in rheumatoid arthritis patients on methotrexate therapy. Orthopedics. 1996;19(3):207–10.
  37. Loza E, Martinez-Lopez JA, Carmona L. A systematic review on the optimum management of the use of methotrexate in rheumatoid arthritis patients in the perioperative period to minimize perioperative morbidity and maintain disease control. Clin Exp Rheumatol. 2009;27(5):856–62.
  38. Tanaka N, Sakahashi H, Sato E, Hirose K, Ishima T, Ishii S. Examination of the risk of continuous leflunomide treatment on the incidence of infectious complications after joint arthroplasty in patients with rheumatoid arthritis. J Clin Rheumatol. 2003;9(2):115–8. doi:.https://doi.org/10.1097/01.RHU.0000062514.54375.bd
  39. Fuerst M, Möhl H, Baumgärtel K, Rüther W. Leflunomide increases the risk of early healing complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Rheumatol Int. 2006;26(12):1138–42. doi:.https://doi.org/10.1007/s00296-006-0138-z
  40. den Broeder AA, Creemers MCW, Fransen J, de Jong E, de Rooij D-JR, Wymenga A, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol. 2007;34(4):689–95.
  41. Bibbo C, Anderson RB, Davis WH, Norton J. The influence of rheumatoid chemotherapy, age, and presence of rheumatoid nodules on postoperative complications in rheumatoid foot and ankle surgery: analysis of 725 procedures in 104 patients [corrected] [corrected]. Foot Ankle Int. 2003;24(1):40–4. doi:.https://doi.org/10.1177/107110070302400106
  42. Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int. 2004;25(5):331–5. doi:.https://doi.org/10.1177/107110070402500510
  43. Giles JT, Bartlett SJ, Gelber AC, Nanda S, Fontaine K, Ruffing V, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum. 2006;55(2):333–7. doi:.https://doi.org/10.1002/art.21841
  44. Kawakami K, Ikari K, Kawamura K, Tsukahara S, Iwamoto T, Yano K, et al. Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-alpha blockers: perioperative interruption of tumour necrosis factor-alpha blockers decreases complications? Rheumatology (Oxford). 2010;49(2):341–7. doi:.https://doi.org/10.1093/rheumatology/kep376
  45. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Ustianowski AP, Helbert M, et al.; BSR Biologics Register. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70(10):1810–4. doi:.https://doi.org/10.1136/ard.2011.152769
  46. Momohara S, Kawakami K, Iwamoto T, Yano K, Sakuma Y, Hiroshima R, et al. Prosthetic joint infection after total hip or knee arthroplasty in rheumatoid arthritis patients treated with nonbiologic and biologic disease-modifying antirheumatic drugs. Mod Rheumatol. 2011;21(5):469–75. doi:.https://doi.org/10.3109/s10165-011-0423-x
  47. Suzuki M, Nishida K, Soen S, Oda H, Inoue H, Kaneko A, et al. Risk of postoperative complications in rheumatoid arthritis relevant to treatment with biologic agents: a report from the Committee on Arthritis of the Japanese Orthopaedic Association. J Orthop Sci. 2011;16(6):778–84. doi:.https://doi.org/10.1007/s00776-011-0142-3
  48. Johnson BK, Goodman SM, Alexiades MM, Figgie MP, Demmer RT, Mandl LA. Patterns and associated risk of perioperative use of anti-tumor necrosis factor in patients with rheumatoid arthritis undergoing total knee replacement. J Rheumatol. 2013;40(5):617–23. doi:.https://doi.org/10.3899/jrheum.121171
  49. Scherrer CB, Mannion AF, Kyburz D, Vogt M, Kramers-de Quervain IA. Infection risk after orthopedic surgery in patients with inflammatory rheumatic diseases treated with immunosuppressive drugs. Arthritis Care Res (Hoboken). 2013;65(12):2032–40. doi:.https://doi.org/10.1002/acr.22077
  50. Talwalkar SC, Grennan DM, Gray J, Johnson P, Hayton MJ. Tumour necrosis factor α antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery. Ann Rheum Dis. 2005;64(4):650–1. doi:.https://doi.org/10.1136/ard.2004.028365
  51. Wendling D, Balblanc JC, Brousse A, Lohse A, Lehuede G, Garbuio P, et al. Surgery in patients receiving anti-tumour necrosis factor α treatment in rheumatoid arthritis: an observational study on 50 surgical procedures. Ann Rheum Dis. 2005;64(9):1378–9. doi:.https://doi.org/10.1136/ard.2005.037762
  52. Ruyssen-Witrand A, Gossec L, Salliot C, Luc M, Duclos M, Guignard S, et al. Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol. 2007;25(3):430–6.
  53. Corrao S, Pistone G, Arnone S, Calvo L, Scaglione R, Licata G. Safety of etanercept therapy in rheumatoid patients undergoing surgery: preliminary report. Clin Rheumatol. 2007;26(9):1513–5. doi:.https://doi.org/10.1007/s10067-007-0534-0
  54. Hirano Y, Kojima T, Kanayama Y, Shioura T, Hayashi M, Kida D, et al. Influences of anti-tumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis. Clin Rheumatol. 2010;29(5):495–500. doi:.https://doi.org/10.1007/s10067-009-1346-1
  55. Gilson M, Gossec L, Mariette X, Gherissi D, Guyot M-H, Berthelot J-M, et al. Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study. Arthritis Res Ther. 2010;12(4):R145. doi:.https://doi.org/10.1186/ar3087
  56. Hayata K, Kanbe K, Chiba J, Nakamura A, Inoue Y, Hobo K. Clinical factors related to the efficacy and complications of orthopedic surgery for rheumatoid arthritis with infliximab. Int J Rheum Dis. 2011;14(1):31–6. doi:.https://doi.org/10.1111/j.1756-185X.2010.01579.x
  57. Barnard AR, Regan M, Burke FD, Chung KC, Wilgis EFS. Wound healing with medications for rheumatoid arthritis in hand surgery. ISRN Rheumatol. 2012;2012:251962. doi:.https://doi.org/10.5402/2012/251962
  58. Berthold E, Geborek P, Gülfe A. Continuation of TNF blockade in patients with inflammatory rheumatic disease. An observational study on surgical site infections in 1,596 elective orthopedic and hand surgery procedures. Acta Orthop. 2013;84(5):495–501. doi:.https://doi.org/10.3109/17453674.2013.842431
  59. Somayaji R, Barnabe C, Martin L. Risk factors for infection following total joint arthroplasty in rheumatoid arthritis. Open Rheumatol J. 2013;7(1):119–24. doi:.https://doi.org/10.2174/1874312920131210005
  60. Kubota A, Sekiguchi M, Nakamura T, Miyazaki Y, Suguro T. Does use of a biologic agent increase the incidence of postoperative infection in surgery for rheumatoid arthritis after total joint arthroplasty? Mod Rheumatol. 2014;24(3):430–3. doi:.https://doi.org/10.3109/14397595.2013.844387
  61. Abou Zahr Z, Spiegelman A, Cantu M, Ng B. Perioperative use of anti-rheumatic agents does not increase early postoperative infection risks: a Veteran Affairs’ administrative database study. Rheumatol Int. 2015;35(2):265–72. doi:.https://doi.org/10.1007/s00296-014-3121-0
  62. Tada M, Inui K, Sugioka Y, Mamoto K, Okano T, Kinoshita T, et al. Delayed wound healing and postoperative surgical site infections in patients with rheumatoid arthritis treated with or without biological disease-modifying antirheumatic drugs. Clin Rheumatol. 2016;35(6):1475–81. doi:.https://doi.org/10.1007/s10067-016-3274-1
  63. Kadota Y, Nishida K, Hashizume K, Nasu Y, Nakahara R, Kanazawa T, et al. Risk factors for surgical site infection and delayed wound healing after orthopedic surgery in rheumatoid arthritis patients. Mod Rheumatol. 2016;26(1):68–74. doi:.https://doi.org/10.3109/14397595.2015.1073133
  64. Filippou G, Tacchini D, Adinolfi A, Bertoldi I, Picerno V, Toscano C, et al. Histology of the synovial membrane of patients affected by osteoarthritis and calcium pyrophosphate dihydrate crystal deposition disease vs. osteoarthritis alone: a pilot study. Scand J Rheumatol. 2016;45(6):538–9. doi:.https://doi.org/10.3109/03009742.2016.1150508
  65. Koike R, Takeuchi T, Eguchi K, Miyasaka N ; Japan College of Rheumatology. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol. 2007;17(6):451–8. doi:.https://doi.org/10.3109/s10165-007-0626-3
  66. Goodman SM, Menon I, Christos PJ, Smethurst R, Bykerk VP. Management of perioperative tumour necrosis factor α inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis. Rheumatology (Oxford). 2016;55(3):573–82.
  67. Hirao M, Hashimoto J, Tsuboi H, Nampei A, Nakahara H, Yoshio N, et al. Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab. Ann Rheum Dis. 2009;68(5):654–7. doi:.https://doi.org/10.1136/ard.2008.090068
  68. Momohara S, Hashimoto J, Tsuboi H, Miyahara H, Nakagawa N, Kaneko A, et al. Analysis of perioperative clinical features and complications after orthopaedic surgery in rheumatoid arthritis patients treated with tocilizumab in a real-world setting: results from the multicentre TOcilizumab in Perioperative Period (TOPP) study. Mod Rheumatol. 2013;23(3):440–9. doi:.https://doi.org/10.3109/s10165-012-0683-0
  69. Koike R, Harigai M, Atsumi T, Amano K, Kawai S, Saito K, et al. Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol. 2009;19(4):351–7. doi:.https://doi.org/10.3109/s10165-009-0197-6
  70. Godot S, Gottenberg J-E, Paternotte S, Pane I, Combe B, Sibilia J, et al. Safety of surgery after rituximab therapy in 133 patients with rheumatoid arthritis: data from the autoimmunity and rituximab registry. Arthritis Care Res (Hoboken). 2013;65(11):1874–9. doi:.https://doi.org/10.1002/acr.22056
  71. Nishida K, Nasu Y, Hashizume K, Nakahara R, Ozawa M, Harada R, et al. Abatacept management during the perioperative period in patients with rheumatoid arthritis: report on eight orthopaedic procedures. Mod Rheumatol. 2014;24(3):544–5. doi:.https://doi.org/10.3109/14397595.2013.874758
  72. Fabiano A, De Simone C, Gisondi P, Piaserico S, Lasagni C, Pellacani G, et al. Management of patients with psoriasis treated with biological drugs needing a surgical treatment. Drug Dev Res. 2014;75(Suppl 1):S24–6. doi:.https://doi.org/10.1002/ddr.21189
  73. Smith CH, Anstey AV, Barker JNWN, Burden AD, Chalmers RJG, Chandler DA, et al.; Chair of Guideline Group. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009;161(5):987–1019. doi:.https://doi.org/10.1111/j.1365-2133.2009.09505.x
  74. Fautrel B, Constantin A, Morel J, Vittecoq O, Cantagrel A, Combe B, et al.; Rheumatism and Inflammation Club (CRI) and of the French Society for Rheumatology. Recommendations of the French Society for Rheumatology. TNFalpha antagonist therapy in rheumatoid arthritis. Joint Bone Spine. 2006;73(4):433–41. doi:.https://doi.org/10.1016/j.jbspin.2006.04.001
  75. Ding T, Ledingham J, Luqmani R, Westlake S, Hyrich K, Lunt M, et al.; Standards, Audit and Guidelines Working Group of BSR Clinical Affairs Committee; BHPR. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford). 2010;49(11):2217–9. doi:.https://doi.org/10.1093/rheumatology/keq249a
  76. Gómez Reino J, Loza E, Andreu JL, Balsa A, Batlle E, Cañete JD, et al.; Sociedad Española de Reumatología. [Consensus statement of the Spanish Society of Rheumatology on risk management of biologic therapy in rheumatic patients]. Reumatol Clin. 2011;7(5):284–98. Article in Spanish.
  77. pharmaSuisse. Articles de la CMPS 2016 [Available from: http://www.pharmasuisse.org/fr/Dienstleistungen/publikationen/Pages/AKA.aspx.
  78. Nunes BP, Camargo-Figuera FA, Guttier M, de Oliveira PD, Munhoz TN, Matijasevich A, et al. Multimorbidity in adults from a southern Brazilian city: occurrence and patterns. Int J Public Health. 2016;61(9):1013–20. doi:.https://doi.org/10.1007/s00038-016-0819-7
  79. Goodman SM, Springer B, Guyatt G, Abdel MP, Dasa V, George M, et al. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Rheumatol. 2017;69(8):1538–51. doi:.https://doi.org/10.1002/art.40149
  80. Makino T, Kaito T, Tsuboi H, Fujiwara H, Yonenobu K. Late-onset deep surgical-site infection after posterior lumbar interbody fusion in a patient treated with tocilizumab; unusual changes in inflammatory markers. Eur Spine J. 2014;23(S2, Suppl 2):296–301. doi:.https://doi.org/10.1007/s00586-014-3317-8
  81. Wakabayashi H, Takigawa S, Hasegawa M, Kakimoto T, Yoshida K, Sudo A. Polyarticular late infection of total joint arthroplasties in a patient with rheumatoid arthritis treated with anti-interleukin-6 therapy. Rheumatology (Oxford). 2014;53(6):1150–1. doi:.https://doi.org/10.1093/rheumatology/ket379
  82. Hiroshima R, Kawakami K, Iwamoto T, Tokita A, Yano K, Sakuma Y, et al. Analysis of C-reactive protein levels and febrile tendency after joint surgery in rheumatoid arthritis patients treated with a perioperative 4-week interruption of tocilizumab. Mod Rheumatol. 2011;21(1):109–11. doi:.https://doi.org/10.3109/s10165-010-0343-1
  83. Campbell L, Chen C, Bhagat SS, Parker RA, Östör AJK. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford). 2011;50(3):552–62. doi:.https://doi.org/10.1093/rheumatology/keq343
  84. Au K, Reed G, Curtis JR, Kremer JM, Greenberg JD, Strand V, et al.; CORRONA Investigators. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(5):785–91. doi:.https://doi.org/10.1136/ard.2010.128637
  85. Mathews CJ, Weston VC, Jones A, Field M, Coakley G. Bacterial septic arthritis in adults. Lancet. 2010;375(9717):846–55. doi:.https://doi.org/10.1016/S0140-6736(09)61595-6

Most read articles by the same author(s)